Together, GSK3β and CDK5 constitute important therapeutic targets for AD, that have also prompted the development of respective kinase inhibitors (Li and Götz, 2017; Yu et al., 2021), although none has as yet shown clinical benefit. Here, GSK3B is linked to Alzheimer disease.